We provide you with 20 years of free, institutional-grade data for ZYME stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ZYME. Explore the full financial landscape of ZYME stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$0
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Hollywood Mark | Grant, award...etc | 939 | $22.22 | 2026-07-06 | |
| Hollywood Mark | Sale | -6,120 | $22.67 | $138,762 | 2026-01-13 |
| Hollywood Mark | Derivatives Exercise | 17,666 | 2026-01-13 | ||
| Hollywood Mark | RSU | 17,666 | 2026-01-13 | ||
| Hollywood Mark | Initial | 2026-01-13 | |||
| Galbraith Kenneth | Sale | -47,528 | $27.02 | $1,284,311 | 2025-12-22 |
| Galbraith Kenneth | Derivatives Exercise | 100,000 | 2025-12-22 | ||
| Galbraith Kenneth | RSU | 100,000 | 2025-12-22 | ||
| Ciongoli Gregory Austin | Initial | 2025-08-12 | |||
| Ciongoli Gregory Austin | Grant, award...etc | 415,000 | $12.02 | 2025-08-12 | |
| EcoR1 Capital, LLC | Sale | -41 | $12.71 | $521 | 2025-06-27 |
| EcoR1 Capital, LLC | Open Market Purchase | 55,421 | $11.43 | 2025-05-19 | |
| EcoR1 Capital, LLC | Open Market Purchase | 128,713 | $11.16 | 2025-04-18 | |
| EcoR1 Capital, LLC | Open Market Purchase | 317,208 | $11.84 | 2025-04-07 | |
| EcoR1 Capital, LLC | Open Market Purchase | 127,415 | $11.75 | 2025-04-02 | |
| EcoR1 Capital, LLC | Open Market Purchase | 97,349 | $12.91 | 2025-03-27 | |
| EcoR1 Capital, LLC | Open Market Purchase | 127,198 | $12.93 | 2025-03-24 | |
| EcoR1 Capital, LLC | Open Market Purchase | 228,463 | $12.23 | 2025-03-19 | |
| EcoR1 Capital, LLC | Open Market Purchase | 1,081,980 | $11.49 | 2025-03-13 | |
| EcoR1 Capital, LLC | Open Market Purchase | 141,429 | $13.88 | 2025-01-21 | |
| EcoR1 Capital, LLC | Open Market Purchase | 167,654 | $13.39 | 2025-01-15 | |
| EcoR1 Capital, LLC | Open Market Purchase | 225,119 | $14.07 | 2025-01-10 | |
| Smith Jeffrey T L | Sale | -11,110 | $14.92 | $165,807 | 2025-01-06 |
| Smith Jeffrey T L | Derivatives Exercise | 20,000 | 2025-01-06 | ||
| Smith Jeffrey T L | RSU | 20,000 | 2025-01-06 | ||
| Galbraith Kenneth | Sale | -57,291 | $14.92 | $855,017 | 2025-01-06 |
| Galbraith Kenneth | Derivatives Exercise | 114,332 | 2025-01-06 | ||
| Galbraith Kenneth | RSU | 114,332 | 2025-01-06 | ||
| Moore Paul Andrew | Sale | -21,200 | $14.92 | $316,391 | 2025-01-06 |
| Moore Paul Andrew | Derivatives Exercise | 37,166 | 2025-01-06 | ||
| Moore Paul Andrew | RSU | 37,166 | 2025-01-06 | ||
| EcoR1 Capital, LLC | Open Market Purchase | 363,369 | $14.47 | 2025-01-02 | |
| EcoR1 Capital, LLC | Open Market Purchase | 130,309 | $14.12 | 2024-12-27 | |
| EcoR1 Capital, LLC | Open Market Purchase | 1,254,808 | $13.53 | 2024-12-26 | |
| Moore Paul Andrew | Sale | -9,799 | $10.65 | $104,381 | 2024-01-08 |
| Moore Paul Andrew | Derivatives Exercise | 17,166 | 2024-01-08 | ||
| Moore Paul Andrew | RSU | 17,166 | 2024-01-08 | ||
| Galbraith Kenneth | Sale | -23,904 | $10.65 | $254,630 | 2024-01-08 |
| Galbraith Kenneth | Derivatives Exercise | 47,666 | 2024-01-08 | ||
| Galbraith Kenneth | RSU | 47,666 | 2024-01-08 | ||
| Astle Christopher | Sale | -5,994 | $10.65 | $63,849 | 2024-01-08 |
| Astle Christopher | Derivatives Exercise | 10,500 | 2024-01-08 | ||
| Astle Christopher | RSU | 10,500 | 2024-01-08 | ||
| Astle Christopher | Sale | -886 | $9.13 | $8,089 | 2023-12-11 |
| Astle Christopher | Derivatives Exercise | 1,550 | 2023-12-11 | ||
| Astle Christopher | RSU | 1,550 | 2023-12-11 |
The information provided in this report about ZYME stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Zymeworks Inc(NASDAQ:ZYME) 
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of ...
Website: http://www.zymeworks.com
Founded: 2003
Full Time Employees: 325
Sector: Healthcare
Industry: Biotechnology